Severe Mpox and Uncontrolled HIV Co-Infection in Lagos, Nigeria – A Case Report
Main Article Content
Keywords
HIV, Co-Infection, severe mpox, cutaneous manifestation
Abstract
Mpox, a re-emerging orthopoxvirus infection, shares clinical similarities with smallpox but is typically less severe. However, immunosuppressed individuals, including those with uncontrolled HIV infection, are at risk for severe and atypical clinical presentations of mpox. We report the case of a 40-year-old Nigerian man living with HIV who was non-adherent to antiretroviral therapy (ART) and presented with extensive vesiculopustular eruptions that evolved into vegetative, ulcerated plaques accompanied by fever, lymphadenopathy, and significant weight loss. Laboratory evaluation showed profound immunosuppression (CD4 <20 cells/μL), and polymerase chain reaction (PCR) testing for mpox was positive. He required 14 weeks of inpatient care, including supportive therapy, broad-spectrum antimicrobials, and intensive wound management. Mpox-specific antiviral therapies were unavailable. Although he achieved clinical recovery, he developed post-inflammatory alopecia, dyspigmentation, and significant psychological distress. This case highlights the risk of severe and prolonged mpox in people living with advanced HIV, the importance of early recognition and microbiological confirmation via PCR, and the need for multidisciplinary supportive care, including infection control, wound and skin management, ART optimisation, and mental-health support. Mpox-specific antivirals should also be made more accessible for patients with severe disease.
References
2. WHO. Mpox [Internet]. [cited 2025 Mar 6]. Available from: https://www.who.int/news-room/fact-sheets/detail/mpox
3. Yinka-Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, Badaru S, et al. Reemergence of human monkeypox in Nigeria, 2017. Emerg Infect Dis. 2018;24(6):1149. https://doi.org/10.3201/eid2406.180017
4. Iroezindu MO, Crowell TA, Ogoina D, Yinka-Ogunleye A. Human mpox in people living with HIV: epidemiologic and clinical perspectives from Nigeria. AIDS research and human retroviruses. 2023 Nov 1;39(11):593-600. https://doi.org/10.1089/aid.2023.0034
5. Parker E, Omah IF, Varilly P, Magee A, Ayinla AO, Sijuwola AE, et al. Genomic epidemiology uncovers the timing and origin of the emergence of mpox in humans. medRxiv. 2024; doi: https://doi.org/10.1101/2024.06.18.24309104
6. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. N Engl J Med. 2022 Aug 25;387(8):679–91. https://doi.org/10.1056/nejmoa2207323
7. Miller MJ. Severe monkeypox in hospitalised patients—United States, August 10–October 10, 2022. MMWR Morb Mortal Wkly Rep. 2022;71. https://doi.org/10.15585/mmwr.mm7144e1
8. Mungmunpuntipantip R, Wiwanitkit V. Monkeypox in HIV Infected Cases: A Summary on Clinical Presentation of 27 Cases. Infect Chemother. 2022;54(3):549. https://doi.org/10.3947/ic.2022.0104
9. Echekwube P, Mbaave P, Abidakun O, Utoo B, Swende T. Human Monkeypox and Human Immunodeficiency Virus Co-infection: A Case Series in Makurdi, Benue State, Nigeria. J Biomed Res Clin Pract. 2020;3(2):375–81. https://api.semanticscholar.org/CorpusID:225325914
10. Oiwoh, S. O., Ibekwe, P., Ajani, A., Cole-Adeife, F., Olanrewaju, F., Oripelaye, M., Akinboro, A., Akinkugbe, A., & Mohammed, T. (2023). Systemic and Dermatologic Impact of Mpox: An Overview of Guideline-Based Management for Nigerian Healthcare Workers: Nigerian Medical Journal, 64(1), 4–12. https://doi.org/10.60787/nmj.v64i1.142
11. Oiwoh S, Abdullahi N, Oyakhire N, Babba Z, Umar A, Cole-Adeife O, Ibekwe P, Mohammed T, Otike-Odibi B. Mpox Protocol by the Nigerian Association of Dermatologists: a Resource for Appropriate Clinical and Public Health Response. NIGERIAN JOURNAL OF DERMATOLOGY. 2023;13(3). https://nigjdermatology.com/index.php/NJD/article/view/237/221
12. Ogoina D, Mohammed A, Yinka-Ogunleye A, Ihekweazu C. A case of suicide during the 2017 monkeypox outbreak in Nigeria. IJID Reg. 2022 Apr 25;3:226-227. https://doi.org/10.1016/j.ijregi.2022.04.004
